DOCSLIB.ORG

Information to Users

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information to Users INFORMATION TO USERS The most advanced technology has been used to photograph and reproduce this manuscript from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information Company 300 North Z eeb Road, Ann Arbor, Ml 48106-1346 USA 313.'761-4700 800/521-0600 Order Number 9031178 Antiulcer activity of the calcium antagonist propyl-mcthylcnedioxyindene Wong, Wai-shiu Fred, Ph.D. The Ohio State University, 1990 UMI 300 N. ZccbRd. Ann Arbor, MI 48106 ANTIULCER ACTIVITY OF THE CALCIUM ANTAGONIST FROPYL-METHYLENEDIOXYINDENE DISSERTATION Presented In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Wai-shiu Fred Wong, U.S. P h arm ., M.S. t\t ijt >Jt >{r The Ohio State University 1990 Dissertation Committee: Approved By Dr. Ralf G. Rahwan Dr. Robert L. Stephens Jr. Dr. Norman J. Uretsky A dvisor Dr. Lane J. Wallace College of Pharmacy To God for giving me wisdom to explore the physical nature of man whom He creates, and to my parents for their sacrifices, and their unceasing love, support and encouragement, and to Amanda for her love, concern and understanding. 11 ACKNOWLEDGMENTS I want to express my sincere appreciation and gratitude to: Dr. Ralf G. Rahwan for his guidance and encouragement, and his persistent enthusiasm and confidence in my research works. Drs. Robert L. Stephens, Jr., Norman J. Uretsky, and Lane J. Wallace for their helpful suggestions and constructive criticisms, and special thanks to Dr. Wallace for his excellent advice in statistics and computer instructions, and to Dr. Stephens for his active participation in my experiments. Dr. McKay for his guidance in taking photomicrographs from microscopic s lid e s . Drs. Dennis R. Feller, Popat N. Patil and Allan M. Burkman for their constant concerns and suggestions. iii VITA November 16, 1961 .............................. Born - Kowloon, Hong Kong 1985 ......................................... ............. B.S, in Pharmacy, The St. John's University, Jamaica, New York 1985 - 1990 ................................................. Graduate Teaching Associate, College of Pharmacy, The Ohio State University, Columbus, Ohio 1988 .................................................................. M.S . in Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio PUBLICATIONS Wong, W.S.F.: Intracellular actions of calcium antagonists in saponin­ skinned vascular smooth muscle. M.Sc. Thesis, The Ohio State University, Columbus, Ohio, 1988. Wong, W.S.F. and Rahwan, R.G.: Pharamcolglcal actions of the calcium antagonist propyl-methylenedioxylndene in skinned vascular smooth muscle. Can. J, Physiol. Pharmacol. 66: 1041-1047, 1988. Rahw an, R.G. and Wong, W.S.F. : Site of action of the calcium antagonist propyl-methylenedioxylndene (pr-MDI) in skinned vascular smooth muscle. 4th Int. Congr. Cell Biol. Abst. P10.1.2, 1988. Wong, W.S.F. and Rahwan, R.G.: Examination of the potential antiepileptic activity of calcium antagonists with different sites of action. Gen. Pharmacol. 20: 309-312, 1989. Wong, W.S.F. and Rahwan, R.G. : Anti ulcer activity of the calcium antagonist propyl-methylenedloxyindene. Pharmacologist. Abst. 149, 1989. iv Wong, W.S.F. and Rahwan, R.G.: Antiulcer activity of the calcium antagonist propyl-methylenedioxyindene. I. Effect on cold-restraint stress-induced ulcers in rats. Gen. Pharmacol. 21: 321-325, 1990. Wong, W.S.F. and Rahwan, R.G.: Antiulcer activity of the calcium antagonist propyl-methylenedioxyindene. II, Effects on acid secretion and gastric emptying in rats. Gen. Pharmacol. 21: 327-331, 1990. FIELDS OF STUDY Major Field: Pharmacology Smooth Muscle Pharmacology - Dr. R.G. Rahwan Pharmacology of Calcium - Dr. R.G. Rahwan Gastrointestinal Pharmacology - Dr. R.G. Rahwan and D r. R.L. Stephens, Jr. v TABLE OF CONTENTS PAGE DEDICATION ..................................................................................................................... ii ACKNOWLEDGMENTS ................................................................................................... iil VITA ....................................................................................................................................... Iv LIST OF TABLES ............................................................................................................ x LIST OF FIGURES .......................................................................................................... xi CHAPTER I INTRODUCTION ................................................................................. 1 1.1 Anatomy of the Stomach and the Duodenum ............................ 1 1.2 Histophysiology of the Gastric Glands ..................................... 12 1.3 Regulations of Gastric Acid Secretion .......... 17 1.4 Pathogenesis of Peptic Ulcer Disease ................................................. 26 1.4.1 Experimental models of gastric ulcers ......................................... 32 1.4.1.1 Cold-restraint stress ulcers............... 33 1.4.1.2 TRH-lnduced gastric ulcerations ............................................ 35 1.4.1.3 Cysteamlne-induced duodenal ulcers ...................................... 38 1.5 Pharmacology of Antiulcer Drugs .......................................................... 41 1.5.1 Antisecretory agents ............................................................................. 41 1.5.1.1 Hz-receptor antagonists ....................... 41 1.5.1.2 Antimuscarinic agents ............... 46 1.5.1.3 Anti gastrin agents ............................................................................ 49 vl 1.5.1.4 H+/K+-ATPase inhibitors ............................................................... 51 1.5.1.5 A ntacids .................................................................................................. 57 1.5.2 Mucosal protective agents ..................................................................... 58 1.5.2.1 Prostaglandins ...................................................................................... 58 1.5.2.2 Sucralfate ................................................................................................ 61 1.5.2.3 Colloidal bismuth subcitrate .................... 64 1.6 Calcium Antagonists and Peptic Ulcer Disease .............................. 66 1.6.1 Calcium channel blockers ..................................................................... 67 1.6.2 Intracellular calcium antagonists ..................................................... 71 1.6.3 Effects of calcium antagonists on experimental ulcers ...................... 75 CHAPTER II RATIONALE AND AIMS OF THIS STUDY ..............................79 CHAPTER III ANTIULCER ACTIVITY OF THE CALCIUM ANTAGONIST PROPYL-METHYLENEDIOXYINDENE. EFFECTS ON COLD-RESTRAINT STRESS-INDUCED ULCERS, ACID SECRETION, MAST CELL DEGRANULATION AND GASTRIC EMPTYING IN RATS .............................................................................................. 83 3.1 Introduction .................. 83 3.2 Methods and Materials ........................................................... 86 3.2.1 Effect of pr-MDI on cold-restralnt stress-indi .ied ulcers .............................................................................. 86 3.2.2 Effect of pr-MDI on gastric acid secretion .............................. 87 3.2.3 Effect of pr-MDI on mast cell degranulation .......... 88 3.2.4 Effect of pr-MDI on gastric emptying ...................... 89 vii 3,2.5 Materials and data analysis ............................................................... 91 3.3 Results ......................................................................................................... 92 3.3.1 Effect of pr-MDI on cold-restralnt stress-induced ulcers .................. 92 3.3.2 Effect of pr-MDI on gastric acid secretion ............................... 96 3.3.3 Effect of pr-MDI on mast cell degranulation ...................... 98 3.3.4 Effect of pr-MDI on gastric emptying ........................................ 101 3.4 Discussion .......................................................................................................... 101 CHAPTER IV ANTIULCER ACTIVITY OF THE CALCIUM ANTAGONIST PROPYL-METHYLENEDIOXYINDENE,
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Gastric H,K-Atpase As a Drug Target
    UCLA UCLA Previously Published Works Title Gastric H,K-ATPase as a drug target Permalink https://escholarship.org/uc/item/1g5606x9 Journal Digestive Diseases and Sciences, 51(5) ISSN 0163-2116 Authors Shin, Jai M Sachs, G Publication Date 2006-05-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California The Gastric H,K-ATPase as a Drug Target Jai Moo Shin and George Sachs* Department of Physiology and Medicine, University of California at Los Angeles, and VA Greater Los Angeles Healthcare System, Los Angeles, California, CA90073, USA * To whom correspondence should be addressed: at Membrane Biology Laboratory, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd., Bldg. 113, Rm. 324, Los Angeles, CA 90073 Tel: (310) 268-4672 Fax: (310) 312-9478 e-mail: [email protected] 1 Introduction Gastric acid is secreted by parietal cells in the stomach. These have two known acid stimulatory receptors the H2-receptor and the muscarinic M3 receptor. Gastrin, the major endocrine activator of acid secretion, exerts its action via release of histamine from the ECL cell as does pituitary adenylate cyclase activating peptide (PACAP), a neural mediator of activation of acid secretion. Antagonists of the former two stimulants inhibit gastric acid secretion. Cholinergic receptor antagonists have many side effects and are relatively weak inhibitors at therapeutic doses as compared toH2-receptor antagonists. These drugs were widely developed in the 1970’s and 1980’s and became the first really useful medications for healing of peptic ulcers. However, although good for healing peptic ulcers, they were less effective in treatment of erosive esophagitis.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Gastro-Duodenal Ulcers Associated with the Use of Non-Steroidal Anti-Inflammatory Drugs: a Systematic Review of Preventive Pharmacological Interventions
    Gastro-duodenal Ulcers Associated with the Use of Technology Non-steroidal Anti- inflammatory Drugs: A Systematic Review Report of Preventive Issue 38 September 2003 Pharmacological Interventions Publications can be requested from: CCOHTA 600-865 Carling Avenue Ottawa, Ontario, Canada K1S 5S8 Tel. (613) 226-2553 Fax. (613) 226-5392 Email: [email protected] or download from CCOHTA’s web site: http://www.ccohta.ca Cite as: Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2003. Technology report no 38. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CCOHTA. CCOHTA is a non-profit organization funded by the federal, provincial and territorial governments. Legal Deposit - 2003 National Library of Canada ISBN: 1-894620-92-5 (print) ISBN: 1-894620-93-3 (electronic version) Publications Mail Agreement Number: 40026386 Canadian Coordinating Office for Health Technology Assessment Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Anti-inflammatory Drugs: A Systematic Review of Preventive Pharmacological Interventions Alaa Rostom MD MSc FRCPC1 1 Catherine Dubé MD MSc FRCPC 1 Emilie Jolicoeur MD 2 Michel Boucher BPharm MSc 2 Janet Joyce MLS September 2003 ________________________ 1 University of Ottawa, Ottawa, Ontario 2 Canadian Coordinating Office for Health Technology Assessment, Ottawa, Ontario Reviewers These individuals kindly provided comments on this report. External Reviewers Isabelle Chabot, PhD Betsy Miller, BScPharm MSc Manager, Health Economics and Executive Director Outcomes Research Patient Access and Outcomes Research Merck Frosst Canada & Co.
    [Show full text]
  • Drug Treatment of Peptic Ulcer Disease Bali A
    SMGr up Drug Treatment of Peptic Ulcer Disease Bali A* - University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab Uni versity,*Corresponding India author: - - Alka Bali, Department of Pharmaceutical Chemistry, University In stitute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandi com garh,160014, India, Tel: 91-172-2541142; Fax: 91-172-541142; E-mail: alka.bali@rediffmail. Published Date: April 16, 2016 ABSTRACT Peptic ulcer disease is a widely prevalent upper gastrointestinal disorder worldwide. Gastric hypersecretion is recognized as the prime underlying cause of this disease. Earlier approaches towards alleviation of this disease have primarily focussed on symptomatic treatment of gastric hypersecretion with anti-secretory agents. Histamine H2 successful mechanistic intervention with acid hypersecretion and the prototypic drug cimetidine receptor antagonists represented the first earned the title of ‘first blockbuster drug’ due to its stupendous sales. Cimetidine, ranitidine2 and famotidine remained as first-line therapy for peptic ulcer disease for a very long time. H +/K + receptor antagonists had some limitations such as, ineffective daytime acid control, development of tolerance during therapy and acid rebound. Identification of the proton pump, H -ATPase, as final source of gastric acid secretion led to development of another novel class of antisecretory acid suppression compared to the H agents, termed as proton pump inhibitors2 (PPIs). These agents gave more potent and reproducible Peptic Ulcer Disease | www.smgebooks.com receptor antagonists and soon became first line drugs1 Copyright Bali A.This book chapter is open access distributed under the Creative Commons Attribution 4.0 International License, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,261,537 B1 Klaveness Et Al
    USOO626.1537B1 (12) United States Patent (10) Patent No.: US 6,261,537 B1 Klaveness et al. (45) Date of Patent: *Jul.17, 2001 (54) DIAGNOSTIC/THERAPEUTICAGENTS 5,632,983 5/1997 Tait et al.. HAVING MICROBUBBLES COUPLED TO 5,643,553 * 7/1997 Schneider et al. .................. 424/9.52 ONE OR MORE VECTORS 5,650,156 7/1997 Grinstaff et al. ..................... 424/400 5,656.211 * 8/1997 Unger et al. .......................... 264/4.1 5,665,383 9/1997 Grinstaff et al. (75) Inventors: Jo Klaveness; Pál Rongved; Anders 5,690,907 11/1997 Lanza et al. .......................... 424/9.5 Høgset; Helge Tolleshaug, Anne 5,716,594 2/1998 Elmaleh et al. Naevestad; Halldis Hellebust; Lars 5,733,572 3/1998 Unger et al.. Hoff, Alan Cuthbertson; Dagfinn 5,780,010 7/1998 Lanza et al. Levhaug, Magne Solbakken, all of 5,846,517 12/1998 Unger. Oslo (NO) 5,849,727 12/1998 Porter et al.. 5,910,300 6/1999 Tournier et al. .................... 424/9.34 (73) Assignee: Nycomed Imaging AS, Oslo (NO) FOREIGN PATENT DOCUMENTS (*) Notice: This patent issued on a continued pros ecution application filed under 37 CFR 2 145 505 4/1994 (CA). 19 626 530 1/1998 (DE). 1.53(d), and is subject to the twenty year 0 727 225 8/1996 (EP). patent term provisions of 35 U.S.C. WO91/15244 10/1991 (WO). 154(a)(2). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). Subject to any disclaimer, the term of this WO 94/28873 12/1994 (WO).
    [Show full text]
  • The Novel Acid Pump Antagonists for Anti-Secretory Actions with Their Peculiar Applications Beyond Acid Suppression
    Review J. Clin. Biobem. Nutr., 38, 1–8, January 2006 The Novel Acid Pump Antagonists for Anti-secretory Actions with Their Peculiar Applications Beyond Acid Suppression Marie Yeo,1 Dong Kyu Kim,1 In Sik Chung,2 Byoung Seok Moon,3 Keun Seog Song,3 and Ki-Baik Hahm1,* 1Genome Research Center for Gastroenterology and Department of Gastroenterology, Ajou University School of Medicine, Suwon 443-721, Korea 2Kangnam St. Mary Hospital, Catholic University School of Medicine, Seoul 137-701, Korea 3Yuhan Corp., Seoul 156-754, Korea Received 28 October, 2005; Accepted 31 October, 2005 Summary The H+/K+-ATPase of gastric parietal cell exchanges luminal K+ for cytoplasmic + − H , of which outcome is gastric acidification with outflux of hydronium ion (H3O ). Secretion of gastric acid from the H+/K+-ATPase is stimulated by neuronal sensing and elaborately regulated various neuronal transmitters and hormones, consequently resulting in anchoring of the H+/K+-ATPase in canaliculi membrane of gastric parietal cell. Since hypersecretion of gastric acid or a defect of its barrier function is considered as a principal casual factor in the acid-related diseases such as duodenal and gastric ulcer, reflux esophagitis, and some types of gastritis, the development of anti-secretory agents including PPIs (proton pump inhibitors) and H2-RAs (histamine type 2 receptor antagonists) has revolutionized during the second millennium. Similar considerations applying to design of compounds substituting K+ led to the development of acid pump antagonists (APAs), of which advantages are independent of secretory status, no lag time required, reversible in actions allowing “on-demand dosage”. Our recent studies revealed that these inhibitors of H+/K+-ATPase could be extensively applied for the selective induction of cancer cell apoptosis, a significant anti-inflammatory and gastro- protective action beyond acid suppression.
    [Show full text]
  • Research Journal of Pharmaceutical, Biological and Chemical Sciences
    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences Proton Pump Inhibitors: A Brief Overview of Discovery, Chemistry and Process Development. Venkata Madhavi Y*, and Gaikwad Nikhil Baliram. Department of Process Chemistry, National Institute of Pharmaceutical Education and Research(NIPER)- Hyderabad, Balanagar, Telangana, India. ABSTRACT Proton pump inhibitors (PPIs) are the most potent gastric acid–suppressing agents in clinical use. Omeprazole was the first effective proton pump inhibitor approved by US FDA. From then a series of proton pump inhibitors have been developed and introduced into the market.These compounds primarily contain a substituted benzimidazole moiety and a substituted pyridine connected by a sulfoxide linkage. Recently these compounds also have been reported to possess anti-cancer activity. Keywords: Proton pump inhibitors; Benzimidazole; asymmetric oxidation;chloromethylpyridine *Corresponding author March – April 2016 RJPBCS 7(2) Page No. 2180 ISSN: 0975-8585 INTRODUCTION Proton pump inhibitors (PPIs) are drugs which irreversibly inhibit proton pump (H+/K+ ATPase) function and are the most potent gastric acid–suppressing agents in clinical use. PPI’s are a class of very effective and generally safe medicines used to treat heart burn, Gastro Oesophageal Reflux Disease (GERD) and gastric ulcers. In 2014, sales of the top ten proton pump inhibitors made up $9.2 billion in U.S. prescription sales, according to IMS Health. One of them NEXIUM was the top selling of all the drugs earning nearly $ 6 billion according to a research firm IMS which compiled a rolling 12-month history (Oct 2013 to Sept 2014) of the top 100 drugs by total prescriptions and total sales in the United States.
    [Show full text]
  • Les Maladies Du Système Digestif Haut: Physiopathologie, Diagnostic Et
    Les maladies du système digestif haut : physiopathologie, diagnostic et place des IPP dans la prise en charge thérapeutique Elyes Kahia To cite this version: Elyes Kahia. Les maladies du système digestif haut : physiopathologie, diagnostic et place des IPP dans la prise en charge thérapeutique. Sciences pharmaceutiques. 2015. dumas-01187977 HAL Id: dumas-01187977 https://dumas.ccsd.cnrs.fr/dumas-01187977 Submitted on 28 Aug 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE DE BORDEAUX COLLEGE SCIENCES DE LA SANTE U.F.R DES SCIENCES PHARMACEUTIQUES Année 2015 Thèse N° 54 Thèse pour l’obtention du DIPLOME D’ETAT DE DOCTEUR EN PHARMACIE Présentée et soutenue publiquement Le 11 mai 2015 Par Elyes KAHIA Né le 31 mars 1988 à Tunis LES MALADIES DU SYSTÈME DIGESTIF HAUT : PHYSIOPATHOLOGIE, DIAGNOSTIC ET PLACE DES IPP DANS LA PRISE EN CHARGE THÉRAPEUTIQUE Directeur de thèse Monsieur Stéphane MOREAU Jury M. Christian TOUSSAINT Maître de Conférences Président M. Stéphane MOREAU Maître de Conférences Assesseur M. Jean-Charles LEDIT Docteur en Pharmacie Assesseur Remerciements A Monsieur le Professeur Christian TOUSSAINT, qui a accepté de présider le jury de ma thèse.
    [Show full text]